Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib first-line treatment study in early chronic phase Philadelphia chromosome-positive chronic myeloid leukemia
2011-002787-25Phase 3Completed
- Sponsor
- GIMEMA
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Primary endpoint: Complete molecular response (CMR4) rate. Started Feb 2012; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2011-002787-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002787-25.